Tenpoint Therapeutics
Founded 2019 · 132 employees on LinkedIn · 3 known investors
Tenpoint Therapeutics develops treatments for age-related ophthalmic conditions, with an initial focus on presbyopia care for the aging eye. The company works with eye care professionals to advance therapies in the ophthalmology market.
Investors · 3
Competitors · 3
by search overlap
Zeiss56 shared keywordsZEISS develops optical and optoelectronic products spanning eyeglass lenses and vision testing, medical technology for ophthalmology and microsurgery, semiconductor manufacturing equipment, industrial measurement and microscopy, and camera and consumer optics. It serves patients, industrial manufacturers, semiconductor makers, scientists, and consumers across ophthalmic, medical, industrial, and optics markets.
Myeyedr52 shared keywordsMyEyeDr. operates a network of local optometry practices offering comprehensive eye exams, prescription eyewear, and eye health services for patients of all ages. It sells designer glasses, sunglasses, and readers, accepts a wide range of vision insurance plans, and provides brands including Oakley, Ray-Ban, and Maui Jim.
Ocumetra46 shared keywordsOcumetra provides myopia management software for eye care professionals and optometrists, offering data-driven axial length estimation, patient communication visuals, and treatment monitoring tools. It also offers API integrations with EHR systems and devices, and supports compliance with World Council of Optometry standards.
Companies competing with Tenpoint Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Tenpoint Therapeutics do?
- Tenpoint Therapeutics develops treatments for age-related ophthalmic conditions, with an initial focus on presbyopia care for the aging eye. The company works with eye care professionals to advance therapies in the ophthalmology market.
- Who are Tenpoint Therapeutics's investors?
- Tenpoint Therapeutics's investors include AdBio partners, F-Prime Capital, Sofinnova Partners.